• Publications
  • Influence
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.
The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC)   Developed with the special contribution of the European Heart Rhythm Association (EHRA) of theExpand
  • 2,870
  • 144
  • PDF
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.
BACKGROUND Angiotensin-converting-enzyme (ACE) inhibitors such as captopril reduce mortality and cardiovascular morbidity among patients with myocardial infarction complicated by left ventricularExpand
  • 2,226
  • 64
  • PDF
Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction.
BACKGROUND The presence of coexisting conditions has a substantial effect on the outcome of acute myocardial infarction. Renal failure is associated with one of the highest risks, but the influenceExpand
  • 1,761
  • 61
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.
Authors/Task Force Members: Paulus Kirchhof* (Chairperson) (UK/Germany) Stefano Benussi* (Co-Chairperson) (Switzerland), Dipak Kotecha (UK), Anders Ahlsson (Sweden), Dan Atar (Norway), BarbaraExpand
  • 1,781
  • 41
  • PDF
Rosuvastatin in older patients with systolic heart failure.
BACKGROUND Patients with systolic heart failure have generally been excluded from statin trials. Acute coronary events are uncommon in this population, and statins have theoretical risks in theseExpand
  • 942
  • 34
Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both.
BACKGROUND The risk of sudden death from cardiac causes is increased among survivors of acute myocardial infarction with reduced left ventricular systolic function. We assessed the risk and timeExpand
  • 672
  • 12
Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double‐blind, randomized comparison of two uptitration regimens
To assess the tolerability of initiating/uptitrating sacubitril/valsartan (LCZ696) from 50 to 200 mg twice daily (target dose) over 3 and 6 weeks in heart failure (HF) patients (ejection fractionExpand
  • 122
  • 10
  • PDF
Changes in Ventricular Size and Function in Patients Treated With Valsartan, Captopril, or Both After Myocardial Infarction
Background—Angiotensin-converting enzyme (ACE) inhibitors have been shown to attenuate left ventricular (LV) enlargement in association with reducing mortality after myocardial infarction (MI).Expand
  • 214
  • 9
  • PDF
An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT registry.
AIMS We analysed the contemporary incidence, outcomes, and predictors of heart failure (HF) and/or left ventricular systolic dysfunction (LVSD) before discharge in patients with acute myocardialExpand
  • 142
  • 9